Dyslipidemia Drug-Treated Population To Grow 4% Annually, According To A New Study From Decision Resources

Pfizer and Merck Schering-Plough to Fight Back Against Generic Erosion of Two Leading Statins

August 31, 2004–Waltham, Mass.--Decision Resources, Inc., one of the world’s leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the overall dyslipidemia drug-treated population will increase by 4% annually. Primary factors driving the rise in drug treatment in this population include increasing awareness of its coronary heart disease risk coupled with the availability of low-cost, generic statin substitutes to treat these patients.

The new Pharmacor study entitled Dyslipidemia also finds that Pfizer and Merck plan to fight back against generic erosion of atorvastatin and simvastatin, two leading statins.

< BACK